FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response	: 0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

						Т		. ,				прапу Аст С	,, 1040		_					
1. Name and Address of Reporting Person*  Lucchino David L.							2. Issuer Name and Ticker or Trading Symbol Frequency Therapeutics, Inc. [FREQ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
Luccinio David L.														X Dire		or 10% (		10% Ov	vner	
(Last)	(	First)	(N	/liddle)		3. Date of Earliest Transaction (Month/Day/Year)							X	Office below	er (give title v)		Other (specify below)			
C/O FREQUENCY THERAPEUTICS, INC.						0//13	07/13/2023										CEO			
75 HAYDEN AVE, SUITE 300					4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)						
																X Form filed by One Reporting Person				
(Street) LEXINO	LEXINGTON MA 02421														Form filed by More than One Reporting Person					
(City)	Rule 10b5-1(c) Transaction Indication												on							
		X Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.																		
			Table I	l - No	n-Deriva	tive S	ecui	rities	Acc	uired,	Dis	posed of	, or I	3ene	ficial	ly Owr	ned			
1. Title of Security (Instr. 3)  2. Transaction Date (Month/Day/					Execution Date,			ate,	Transaction Disposed Code (Instr. 5)		Disposed C	ies Acquired (A) Of (D) (Instr. 3, 4			Securi Benefi Owned Follow	ities Fo icially (D) d Ind ving (In		n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
										Code	v	Amount	(A) (D)	or Pr	ice		rted action(s) . 3 and 4)			
Common Stock 07/13/20						023				S		2,646(1)	Г	\$	0.39 <sup>(2)</sup>	707,397		D		
Common Stock 07/14/20						023				S		1,815(1)	D	\$	0.59 <sup>(3)</sup>	705,582		D		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
					(e.g., pu	ts, ca	is, v	varra	ants,	option	15, (	convertib	ie se	curit	ies)					
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution urity or Exercise (Month/Day/Year) if any			tion Date, Trans		saction Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisabl Expiration Date (Month/Day/Year)		ate	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficial! Owned Following Reported Transactio (Instr. 4)	y	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
						Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amou or Numb of Share	er					

## **Explanation of Responses:**

- 1. Represents a portion of the shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of the restricted stock units pursuant to a Rule 10b5-1 trading plan entered into on March 22, 2022 and does not represent discretionary trades by the Reporting Person.
- 2. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.38 to \$0.40. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.
- 3. This transaction was executed in multiple trades through a broker-dealer at prices ranging from \$0.58 to \$0.63. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

/s/ James P. Abely, Attorneyin-Fact for David L. Lucchino 07/17/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.